JPH11512297A - 免疫化または遺伝子療法用の筋肉特異的調節要素を含有してなるｄｎａ構築物 - Google Patents

免疫化または遺伝子療法用の筋肉特異的調節要素を含有してなるｄｎａ構築物

Info

Publication number
JPH11512297A
JPH11512297A JP9512813A JP51281397A JPH11512297A JP H11512297 A JPH11512297 A JP H11512297A JP 9512813 A JP9512813 A JP 9512813A JP 51281397 A JP51281397 A JP 51281397A JP H11512297 A JPH11512297 A JP H11512297A
Authority
JP
Japan
Prior art keywords
muscle
dna
dna construct
vector
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9512813A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11512297A5 (https=
Inventor
リチリャーノ，ジョゼフ・ダブリュー
アラネオ，バーバラ・エイ
Original Assignee
ファーマダイム・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマダイム・インコーポレイテッド filed Critical ファーマダイム・インコーポレイテッド
Publication of JPH11512297A publication Critical patent/JPH11512297A/ja
Publication of JPH11512297A5 publication Critical patent/JPH11512297A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP9512813A 1995-09-19 1996-09-19 免疫化または遺伝子療法用の筋肉特異的調節要素を含有してなるｄｎａ構築物 Ceased JPH11512297A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/530,529 US5795872A (en) 1995-09-19 1995-09-19 DNA construct for immunization
US08/530,529 1995-09-19
PCT/US1996/014829 WO1997011190A2 (en) 1995-09-19 1996-09-19 Dna construct comprising a muscle specific regulatory element for immunization or gene therapy

Publications (2)

Publication Number Publication Date
JPH11512297A true JPH11512297A (ja) 1999-10-26
JPH11512297A5 JPH11512297A5 (https=) 2004-09-30

Family

ID=24113962

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9512813A Ceased JPH11512297A (ja) 1995-09-19 1996-09-19 免疫化または遺伝子療法用の筋肉特異的調節要素を含有してなるｄｎａ構築物

Country Status (6)

Country Link
US (2) US5795872A (https=)
EP (1) EP0851935A2 (https=)
JP (1) JPH11512297A (https=)
AU (1) AU710756B2 (https=)
CA (1) CA2231806A1 (https=)
WO (1) WO1997011190A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513389A (ja) * 2016-04-15 2019-05-30 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 筋ジストロフィーを治療するためのマイクロｒｎａ−２９のアデノ随伴ウイルスベクター送達
JPWO2021107013A1 (https=) * 2019-11-29 2021-06-03
US11534501B2 (en) 2017-10-18 2022-12-27 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
US12257317B2 (en) 2017-03-17 2025-03-25 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
US12491265B2 (en) 2018-06-18 2025-12-09 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020103145A1 (en) * 1999-05-19 2002-08-01 Adrian Bot Immunization of infants
US20060014710A9 (en) * 1996-11-22 2006-01-19 Adrian Bot Immunization of infants
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
JP4180238B2 (ja) 1997-12-09 2008-11-12 株式会社コスモ総合研究所 環状フェノール硫化物のスルホン酸化合物及びその製造方法
WO2000025820A1 (en) * 1998-11-04 2000-05-11 Pharmadigm, Inc. Compounds and methods for genetic immunization
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
DE10014690A1 (de) * 2000-03-24 2001-10-18 Franz Wolfgang M Verfahren zur Isolierung in vito differenzierter Körperzellen
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
CA2442089A1 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
EP1390490B1 (en) * 2001-05-24 2009-04-15 Genzyme Corporation Muscle-specific expression vectors
AU2002357004A1 (en) * 2001-11-20 2003-06-10 Dendreon San Diego Llc Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
CA2492160A1 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
AU2005249450A1 (en) 2004-05-27 2005-12-15 Centocor, Inc. Cynomolgus prostate specific antigen
CA2570563A1 (en) * 2004-06-15 2006-09-28 Centocor, Inc. Method for screening agents against human prostate disease
GB201102091D0 (en) 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
GB201102090D0 (en) 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
EP3049106A1 (en) 2013-09-25 2016-08-03 Zoetis Services LLC Pcv2b divergent vaccine composition and methods of use
EP3268025B1 (en) 2015-03-10 2020-05-06 University of Massachusetts Targeting gdf6 and bmp signaling for anti-melanoma therapy
WO2023008881A1 (ko) * 2021-07-29 2023-02-02 주식회사 에스엠엘바이오팜 발현 시스템 및 이를 포함하는 핵산 기반 약학 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169763A (en) * 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
US5273876A (en) * 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US5266488A (en) * 1988-04-06 1993-11-30 The Regents Of The University Of California Troponin T gene promoter and derivatives thereof
EP0351921A3 (en) * 1988-07-22 1991-07-17 Merck & Co. Inc. Modified beta adrenergic receptor
WO1991011522A1 (en) * 1990-01-26 1991-08-08 Baylor College Of Medicine MUTATED PROMOTER REGION FROM CHICKEN SKELETAL α-ACTIN GENE
US5352595A (en) * 1991-09-03 1994-10-04 Fred Hutchinson Cancer Research Center Myod regulatory region
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU5896394A (en) * 1992-11-10 1994-06-08 Washington University Pars planitis specific polypeptides
DE69333886T2 (de) * 1992-11-18 2006-07-27 Arch Development Corp., Chicago Adenovirus-gelenkter Gen-Transfer zum Herz-und glattem vaskulären Muskel
GB9310441D0 (en) * 1993-05-20 1993-07-07 Royal Free Hosp School Med Gene therapy

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513389A (ja) * 2016-04-15 2019-05-30 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 筋ジストロフィーを治療するためのマイクロｒｎａ−２９のアデノ随伴ウイルスベクター送達
US11298429B2 (en) 2016-04-15 2022-04-12 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of microrna-29 to treat muscular dystrophy
US11406717B2 (en) 2016-04-15 2022-08-09 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of microRNA-29 and micro-dystrophin to treat muscular dystrophy
US11723986B2 (en) 2016-04-15 2023-08-15 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy
US12257317B2 (en) 2017-03-17 2025-03-25 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
US11534501B2 (en) 2017-10-18 2022-12-27 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
US12491265B2 (en) 2018-06-18 2025-12-09 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
JPWO2021107013A1 (https=) * 2019-11-29 2021-06-03
WO2021107013A1 (ja) * 2019-11-29 2021-06-03 国立研究開発法人理化学研究所 アジュバント組成物

Also Published As

Publication number Publication date
US6310196B1 (en) 2001-10-30
EP0851935A2 (en) 1998-07-08
CA2231806A1 (en) 1997-03-27
US5795872A (en) 1998-08-18
WO1997011190A3 (en) 1997-06-26
AU7160296A (en) 1997-04-09
AU710756B2 (en) 1999-09-30
WO1997011190A2 (en) 1997-03-27

Similar Documents

Publication Publication Date Title
JPH11512297A (ja) 免疫化または遺伝子療法用の筋肉特異的調節要素を含有してなるｄｎａ構築物
WO1997011190A9 (en) Dna construct comprising a muscle specific regulatory element for immunization or gene therapy
US5698202A (en) Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
CA2673373C (en) Rsv f-protein and its use
EP0259212B1 (fr) Expression d'un antigène spécifique de tumeur par un virus vecteur recombinant et utilisation de celui-ci pour le traitement préventif ou curatif de la tumeur correspondante
US6235523B1 (en) Vectors for DNA immunization against cervical cancer
KR101745029B1 (ko) 재조합 조류 파라믹소바이러스 백신 및 이의 제조 및 사용 방법
KR20230050328A (ko) Hbv에 대한 rna 레플리콘 백신
IL174848A (en) Nucleic acid construct and vaccine comprising the same for immunizing against a pathogen, allergy or cancer
TW202206598A (zh) 對抗ＳＡＲＳ－ＣｏＶ－２之疫苗及其製品
WO2015181142A1 (en) Cytomegalovirus complexes and uses thereof
KR20230008707A (ko) 코로나바이러스 치료용 백신 조성물
WO2022161495A1 (en) Recombinant sars-cov-2 vaccine
EP1620558B1 (en) Viral vectors expressing fusion of viral large envelope protein and protein of interest
JP2000507229A (ja) ヒト腫瘍遺伝子治療用組換えアデノウイルスベクター
ES2310988T3 (es) Particulas para terapia genica.
JPH11504204A (ja) 免疫回避タンパク質
US20060286114A1 (en) Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof
KR20260028774A (ko) 양이온성 지질을 함유하는 약학적 조성물 및 이의 용도
AU2004231119B2 (en) Viral vectors expressing fusion of viral large envelope protein and protein of interest
CN117229371A (zh) 新型冠状病毒变异毒株的S蛋白突变体及其基因工程化mRNA和疫苗组合物

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060925

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20070115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070213